Chronic rhinosinusitis: the rationale for current treatments

Nsangou Ghogomu, Robert Kern*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Introduction: Chronic rhinosinusitis (CRS) is a broad clinical syndrome linked by mucosal inflammation. Primary treatment modalities are corticosteroids and antibiotics with surgery an option for failures, but the level of supporting evidence is generally low. The primary reason is that CRS is a symptom complex and not a specific disease. Areascovered: The primary treatment modalities for CRS are corticosteroids, antibiotics and surgery. Corticosteroids, which have very broad anti-inflammatory properties, also have the strongest evidence for efficacy. Antibiotics are likely effective in a subpopulation of patients but the various phenotypes and endotypes that make up CRS have thus far been poorly defined. Early surgery as well as biologics may also be more efficacious and cost effective in some phenotypes as well. Expertcommentary: A better understanding of the inflammatory pathways that drive CRS will permit investigators to separate patient groups. This will allow for clinical trials that target specific subpopulations and more personalized therapy for CRS patients in the future.

Original languageEnglish (US)
Pages (from-to)259-270
Number of pages12
JournalExpert Review of Clinical Immunology
Issue number3
StatePublished - Mar 4 2017


  • Chronic rhinosinusitis
  • antimicrobials
  • biologics
  • corticosteroids
  • endoscopic sinus surgery
  • recurrent acute sinusitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Chronic rhinosinusitis: the rationale for current treatments'. Together they form a unique fingerprint.

Cite this